3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Phase 2
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Plasma cell
3
Conditions
Multiple Myeloma
21
Recurrence
3
Neoplasms, Plasma Cell
2
Immunoglobulin Light-chain Amyloidosis
2
Amyloidosis
2
Plasmablastic Lymphoma
1
Interventions
Cyclophosphamide
25
fludarabine
19
Dexamethasone
17
pembrolizumab
13
Rituximab
12
venetoclax
9
Lenalidomide
9
Gemcitabine
9
Etoposide
9
pomalidomide
8
Vincristine
7
glofitamab
6
fludarabine phosphate
6
carfilzomib
6
Temozolomide
6
obinutuzumab
5
daratumumab
5
Prednisone
5
Nivolumab
5
Doxorubicin
5
Cisplatin
5
Calcium Dobesilate
5
Bortezomib
5
zanubrutinib
4
selinexor
4
Immunotherapy, Adoptive
4
Cytarabine
4
Carboplatin
4
Azacitidine
4
ruxolitinib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Recurrence
×
belantamab mafodotin
×
90 days
×
Clear all
NCT05714839
2026-05-22
DREAMM-20
GlaxoSmithKline
Phase 1/2
Recruiting
152 enrolled
NCT05064358
2026-05-05
DREAMM 14
GlaxoSmithKline
Phase 2
Completed
177 enrolled
37 charts
NCT02343042
2026-05-04
STOMP
Karyopharm Therapeutics Inc
Phase 1/2
Active not recruiting
300 enrolled